COSMO Pharmaceuticals N.V. (CMOPF)
OTHER OTC:CMOPF
CMOPF Stock Chart & Stats
$126.00
--
Market closed
$126.00
--
Day’s Range― - ―
52-Week Range$64.95 - $169.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.08K
Market Cap
$1.56B
Enterprise Value$1.33B
Total Cash (Recent Filing)$122.66M
Total Debt (Recent Filing)$4.26M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Jul 20, 2026Next Dividend Ex-DateN/A
Dividend Yield2.72%
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume3,235
30 Day Avg. Volume1,078
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue12.80
Enterprise Value/Gross Profit26.38
Enterprise Value/Ebitda189.44
Forecast
1Y Price Target
$181.60Price Target Upside44.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.13
Revenue Forecast (FY)$134.72M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet With Very Low LeverageMinimal debt and substantial equity provide durable financial flexibility. This conservatism lowers solvency risk, supports continued R&D and commercial activities during downturns, and creates capacity for opportunistic deals or to bridge temporary cash shortfalls without immediate financing.
Ability To Generate Substantial Cash In Strong YearsThe company has demonstrated it can convert revenue into very strong operating and free cash flow in favorable periods. That capability indicates the business model can be self-funding when core products perform, enabling reinvestment, partner funding arrangements, or shareholder returns when performance normalizes.
Niche Focus And Diversified Revenue Model (sales + Licensing)A focused gastroenterology/endoscopy product set combined with both direct commercialization and licensing creates structural advantages: deep clinical expertise, sticky customer relationships, and multiple revenue levers (royalties, milestones, sales) that can smooth income and share development risk with partners.
Bears Say
Sharp Revenue And Profit Decline In 2025A large YoY revenue and margin collapse signals material exposure to one-off events, lumpy licensing or product demand, or concentration risks. Persistent declines reduce reinvestment capacity, make operating margins unreliable, and undermine the predictability needed for multi-period R&D and commercial planning.
Operating And Free Cash Flow Turned Negative In 2025Transitioning from large positive cash generation to cash burn within a year increases reliance on balance-sheet reserves or external financing if the trend persists. Negative operating cash flow limits the firm's ability to self-fund projects, pay dividends, or invest in commercialization without drawing on equity or debt buffers.
Historic Earnings Volatility And Lack Of Consistent ProfitabilityRepeated swings across years indicate the business lacks consistent underlying earnings power. This volatility hampers long-term forecasting, makes milestone-dependent licensing revenues unreliable, and can strain partner and investor confidence, complicating strategic investments and access to capital.
COSMO Pharmaceuticals N.V. News
CMOPF FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was $64.95 and its highest was $169.90 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is $1.56B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 20, 2026 which is in 44 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -$0.116 earnings per share for the quarter, missing the consensus estimate of $0.232 by -$0.348.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of $2.4 which represents an annual dividend yield of 2.72%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate is 0.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -$0.116 in its last earnings report, missing expectations of $0.232. Following the earnings report the stock price went down -10.708%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CMOPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
CMOPF Stock 12 Month Forecast
Average Price Target
$181.60
▲(44.13% Upside)
Ownership Overview
―
Insiders
7.82% Mutual Funds
0.05% Other Institutional Investors
88.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---